Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from VALN

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

MarketBeat

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.

Benzinga

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Benzinga

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

StockNews.com

Why Shares Of Valneva SE Are Soaring Today

Valneva SE (NASDAQ: VALN) shares are trading higher after the company and Pfizer announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal

The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union.

Benzinga

Why Valneva's Shares Are Plunging Today Premarket

Valneva SE (NASDAQ:VALN) warned it might have to reconsider its FY22 financial guidance after the European Commission informed the company of its intent to terminate an advance purchase agreement (APA) for its VLA2001 COVID-19 candidate vaccine. In November, the company signed the APA with the European Commission to supply up to 60 million doses of…

Benzinga

How To Attend Valneva Q1 2022 Earnings Conference Call

Valneva (NASDAQ:VALN) will host a conference call at 09:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Valneva (VALN) Conference Call Follow this link to access the live webcast.

Benzinga

Valneva - Pfizer Post Encouraging Data From Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN) and Pfizer Inc (NYSE:PFE) have reported Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. In pediatric participants (5-17 years old) who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. These…

Benzinga

Valneva Shares Jump As Its COVID-19 Vaccine Receives Conditional Approved In UK

The Healthcare products Regulatory Agency (MHRA) of the U.K. has granted Conditional Marketing Authorization for Valneva SE's (NASDAQ:VALN)COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age. MHRA found that VLA2001 meets safety, quality, and effectiveness standards. This new marketing authorization comes in addition to the emergency use authorization,…

Benzinga

European Recommendation On Valneva's COVID-19 Shot Pushed Into April

Valneva SE (NASDAQ:VALN) now expects a positive recommendation from the European Medicines Agency (EMA) for its VLA2001 COVID-19 candidate vaccine in April. Earlier, the Company expected the European recommendation by the end of March. As announced in February, Valneva received a list of questions as part of the CHMP's initial assessment, to which…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Read Why Valneva's Stock Gained 7% Today

Valneva SE (NASDAQ:VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. The removal of two subjects from the analysis increased the proportion of participants with protective…

Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Valneva Expects European Recommendation On COVID-19 Shot By March End

Valneva SE (NASDAQ: VALN) expects to start delivering its vaccine in Europe soon after it is recommended for conditional approval by the end of March.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Valneva Secures £20M From Scottish Enterprise For Vaccine Development

Valneva SE (NASDAQ: VALN) has been

Benzinga

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

Benzinga

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Why Are Valneva Shares Rising Today Premarket?

Valneva SE (NASDAQ: VALN) expects its COVID-19 vaccine candidate to boost its sales in FY22 considerably, after

Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents

Valneva SE (NASDAQ: VALN) has

Benzinga

Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial

Valneva SE (NASDAQ: VALN) has

1 2

People

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.